Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Pain ; 158(11): 2196-2202, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28825602

RESUMEN

Psoriasis is often accompanied by itch, but the mechanisms behind this symptom remain elusive. Dynamic changes in epidermal innervation have been observed under chronic itch conditions. Therefore, we investigated whether epidermal innervation is altered in the imiquimod-induced psoriasis mouse model, whether blockade of neurotrophic growth factor signaling can reduce these changes, and whether this system can impact psoriatic itch. Over the 7-day time course of imiquimod treatment, the density of epidermal nonpeptidergic nerves significantly increased, whereas the density of peptidergic nerves significantly decreased. The nonpeptidergic epidermal nerves expressed glial cell line-derived neurotrophic factor (GDNF) family receptor GFRα-1 and GFRα-2, the ligand-binding domains for GDNF and neurturin (NRTN). The NRTN mRNA expression was elevated in the skin of imiquimod-treated mice, whereas the GDNF mRNA expression was decreased. Treatment of imiquimod-challenged mice with an NRTN-neutralizing antibody significantly reduced nonpeptidergic nerve density as well as spontaneous scratching. These results indicate that NRTN contributes to an increase in the epidermal density of nonpeptidergic nerves in the imiquimod-induced psoriasis model, and this increase may be a factor in chronic itch for these mice. Therefore, inhibition of NRTN could be a potential treatment for chronic itch in psoriasis.


Asunto(s)
Fibras Nerviosas/patología , Neurturina/metabolismo , Prurito/etiología , Psoriasis/complicaciones , Psoriasis/patología , Piel/inervación , Adyuvantes Inmunológicos/uso terapéutico , Aminoquinolinas/uso terapéutico , Animales , Anticuerpos/uso terapéutico , Péptido Relacionado con Gen de Calcitonina/metabolismo , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/fisiología , Factor Neurotrófico Derivado de la Línea Celular Glial/metabolismo , Receptores del Factor Neurotrófico Derivado de la Línea Celular Glial/genética , Receptores del Factor Neurotrófico Derivado de la Línea Celular Glial/metabolismo , Imiquimod , Masculino , Ratones , Ratones Endogámicos C57BL , Neurturina/genética , Neurturina/inmunología , Psoriasis/tratamiento farmacológico , ARN Mensajero/metabolismo , Receptores Purinérgicos P2X3/metabolismo
2.
Pain ; 157(11): 2536-2543, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27437787

RESUMEN

Itch is a major indicator of psoriasis, but the underlying mechanisms behind this symptom are largely unknown. To investigate the neuronal mechanisms of psoriatic itch, we tested whether mice subjected to the imiquimod-induced psoriasis model exhibit itch-associated behaviors. Mice received daily topical applications of imiquimod to the rostral back skin for 7 days. Imiquimod-treated mice exhibited a significant increase in spontaneous scratching behavior directed to the treated area as well as touch-evoked scratching (alloknesis). To characterize this model, we measured the mRNA expression levels of pruritogens and itch-relevant receptors/channels using real-time reverse transcription PCR. The mRNA expression of MrgprA3, MrgprC11, and MrgprD decreased gradually over time in the dorsal root ganglion (DRG) cells. There was no significant change in the mRNA expression of TRPV1 or TRPA1 in DRG cells. TRPV4 mRNA expression was transiently increased in the DRG cells, whereas TRPM8 mRNA was significantly decreased. The mRNA expression levels of histidine decarboxylase and tryptophan hydroxylase 1, as well as the intensity of histamine and serotonin immunoreactivity, were transiently increased in the skin on day 2, returning to baseline by day 7. Histamine H1-receptor antagonists, chlorpheniramine and olopatadine, significantly inhibited spontaneous scratching on day 2, but not day 7. Neither chlorpheniramine nor olopatadine affected alloknesis on day 2 or day 7. These results may reflect the limited antipruritic effects of histamine H1-receptor antagonists on human psoriasis. The imiquimod-induced psoriasis model seems to be useful for the investigation of itch and its sensitization in psoriasis.


Asunto(s)
Adyuvantes Inmunológicos/toxicidad , Aminoquinolinas/toxicidad , Modelos Animales de Enfermedad , Prurito/inducido químicamente , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Antipruriginosos/uso terapéutico , Clorfeniramina/uso terapéutico , Ganglios Espinales/efectos de los fármacos , Ganglios Espinales/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Histidina Descarboxilasa/genética , Histidina Descarboxilasa/metabolismo , Imiquimod , Masculino , Ratones , Ratones Endogámicos C57BL , Clorhidrato de Olopatadina/uso terapéutico , Dimensión del Dolor , Prurito/tratamiento farmacológico , Prurito/patología , Distribución Aleatoria , Piel/metabolismo , Piel/patología , Canales Catiónicos TRPV/genética , Canales Catiónicos TRPV/metabolismo , Triptófano Hidroxilasa/genética , Triptófano Hidroxilasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...